Short-term topical bevacizumab in the treatment of stable corneal neovascularization

American Journal of Ophthalmology

Volumn 154, Issue 6, 2012, Pages

  Cheng, Sheng Fu ^a,b   Dastjerdi, Mohammad H ^a   Ferrari, Giulio ^a   Okanobo, Andre ^a   Bower, Kraig S ^c   Ryan, Denise S ^d   Amparo, Francisco ^a   Stevenson, William ^a   Hamrah, Pedram ^a   Nallasamy, Nambi ^a   Dana, Reza ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORNEA NEOVASCULARIZATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EYE TOXICITY; FEMALE; HUMAN; MALE; MEAN ARTERIAL PRESSURE; MULTICENTER STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84869087247     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.06.007     Document Type: Article

References (31)

1. J.H. Chang, E.E. Gabison, T. Kato, D.T. Azar Corneal neovascularization Curr Opin Ophthalmol 12 4 2001 242 249 (Pubitemid 32751680)
2. T.J. Liesegang Epidemiology of ocular herpes simplex: natural history in Rochester, Minn, 1950 through 1982 Arch Ophthalmol 107 8 1989 1160 1165 (Pubitemid 19195643)
3. S. Resnikoff, D. Pascolini, D. Etya'ale Global data on visual impairment in the year 2002 Bull World Health Organ 82 11 2004 844 851 (Pubitemid 39573742)
4. R.J. Epstein, R.D. Stulting, R.L. Hendricks, D.M. Harris Corneal neovascularization Pathogenesis and inhibition Cornea 6 4 1987 250 257
5. J. Niederkorn Immune privilege and immune regulation in the eye Adv Immunol 48 1990 191 226 (Pubitemid 20210190)
6. M.R. Dana, J.W. Streilein Loss and restoration of immune privilege in eyes with corneal neovascularization Invest Ophthalmol Vis Sci 37 12 1996 2485 2494 (Pubitemid 26391286)
7. M.G. Maguire, W.J. Stark, J.D. Gottsch Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies Collaborative Corneal Transplantation Studies Research Group Ophthalmology 101 9 1994 1536 1547 (Pubitemid 24347052)
8. A. Naldini, F. Carraro Role of inflammatory mediators in angiogenesis Curr Drug Targets Inflamm Allergy 4 1 2005 3 8 (Pubitemid 40584847)
9. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1 1995 27 31
10. D.T. Azar Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc 104 2006 264 302 (Pubitemid 46495064)
11. S. Amano, R. Rohan, M. Kuroki, M. Tolentino, A.P. Adamis Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization Invest Ophthalmol Vis Sci 39 1 1998 18 22 (Pubitemid 28040457)
12. W. Philipp, L. Speicher, C. Humpel Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas Invest Ophthalmol Vis Sci 41 9 2000 2514 2522 (Pubitemid 30624378)
13. R.L. Avery, D.J. Pieramici, M.D. Rabena Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 3 2006 363 372.e5
14. D. Iturralde, R.F. Spaide, C.B. Meyerle Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study Retina 26 3 2006 279 284 (Pubitemid 44318180)
15. R.L. Avery, J. Pearlman, D.J. Pieramici Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 10 2006 1695 1705.e6
16. J.O. Mason 3rd, M.A. Albert Jr, A. Mays, R. Vail Regression of neovascular iris vessels by intravitreal injection of bevacizumab Retina 26 7 2006 839 841 (Pubitemid 44386115)
17. M.R. Fallah, K. Khosravi, M.N. Hashemian Efficacy of topical bevacizumab for inhibiting growth of impending recurrent pterygium Curr Eye Res 35 1 2010 17 22
18. M.H. Dastjerdi, K.M. Al-Arfaj, N. Nallasamy Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study Arch Ophthalmol 127 4 2009 381 389
19. S.W. Kim, B.J. Ha, E.K. Kim, H. Tchah, T.I. Kim The effect of topical bevacizumab on corneal neovascularization Ophthalmology 115 6 2008 e33 e38
20. Y. Koenig, F. Bock, F. Horn Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization Graefes Arch Clin Exp Ophthalmol 247 10 2009 1375 1382
21. T.P. Quinn, K.G. Peters, C. De Vries, N. Ferrara, L.T. Williams Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium Proc Natl Acad Sci U S A 90 16 1993 7533 7537 (Pubitemid 23249984)
22. C. de Vries, J.A. Escobedo, H. Ueno, K. Houck, N. Ferrara, L.T. Williams The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor Science 255 5047 1992 989 991
23. N. Ferrara, K.J. Hillan, H.-P. Gerber, W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 5 2004 391 400 (Pubitemid 38618122)
24. C. Cursiefen, C. Hofmann-Rummelt, M. Küchle, U. Schlötzer- Schrehardt Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation Br J Ophthalmol 87 1 2003 101 106 (Pubitemid 36071788)
25. M.R. Dana, S.N. Zhu, J. Yamada Topical modulation of interleukin-1 activity in corneal neovascularization Cornea 17 4 1998 403 409 (Pubitemid 28307507)
26. D.R. Anijeet, Y. Zheng, A. Tey Imaging and evaluation of corneal vascularization using fluorescein and indocyanine green angiography Invest Ophthalmol Vis Sci 53 2 2012 650 658
27. D.S. Boyer, A.N. Antoszyk, C.C. Awh Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration Ophthalmology 114 2 2007 246 252 (Pubitemid 46172497)
28. P.J. Rosenfeld, R.M. Rich, G.A. Lalwani Ranibizumab: phase III clinical trial results Ophthalmol Clin North Am 19 3 2006 361 372 (Pubitemid 44279358)
29. J.M. Rosenstein, J.M. Krum New roles for VEGF in nervous tissue - beyond blood vessels Exp Neurol 187 2 2004 246 253 (Pubitemid 38610271)
30. C. Pérez-Rico, J. Benítez-Herreros, M. Castro-Rebollo Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration Cornea 29 8 2010 849 852
31. M.H. Hosny, M.A. Zayed, A.M. Shalaby, I.M. Eissa Effect of intracameral bevacizumab injection on corneal endothelial cells: an in vivo evaluation J Ocul Pharmacol Ther 25 6 2009 513 517